- Home
- ADPT vs AAMI Comparison
ADPT vs AAMI Comparison
Compare ADPT & AAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- AAMI
- Stock Information
- Founded
- ADPT 2009
- AAMI 1980
- Country
- ADPT United States
- AAMI United States
- Employees
- ADPT N/A
- AAMI N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- AAMI Investment Managers
- Sector
- ADPT Health Care
- AAMI Finance
- Exchange
- ADPT Nasdaq
- AAMI Nasdaq
- Market Cap
- ADPT 1.8B
- AAMI 1.6B
- IPO Year
- ADPT 2019
- AAMI N/A
- Fundamental
- Price
- ADPT $12.92
- AAMI $47.17
- Analyst Decision
- ADPT Strong Buy
- AAMI Hold
- Analyst Count
- ADPT 8
- AAMI 3
- Target Price
- ADPT $12.38
- AAMI $35.33
- AVG Volume (30 Days)
- ADPT 2.1M
- AAMI 234.2K
- Earning Date
- ADPT 08-05-2025
- AAMI 07-31-2025
- Dividend Yield
- ADPT N/A
- AAMI 0.09%
- EPS Growth
- ADPT N/A
- AAMI 43.58
- EPS
- ADPT N/A
- AAMI 2.41
- Revenue
- ADPT $205,216,000.00
- AAMI $538,200,000.00
- Revenue This Year
- ADPT $24.39
- AAMI $11.59
- Revenue Next Year
- ADPT $20.44
- AAMI $10.38
- P/E Ratio
- ADPT N/A
- AAMI $19.51
- Revenue Growth
- ADPT 21.60
- AAMI 18.76
- 52 Week Low
- ADPT $3.98
- AAMI $22.56
- 52 Week High
- ADPT $13.37
- AAMI $48.45
- Technical
- Relative Strength Index (RSI)
- ADPT 69.79
- AAMI N/A
- Support Level
- ADPT $10.66
- AAMI N/A
- Resistance Level
- ADPT $13.37
- AAMI N/A
- Average True Range (ATR)
- ADPT 0.81
- AAMI 0.00
- MACD
- ADPT 0.23
- AAMI 0.00
- Stochastic Oscillator
- ADPT 86.82
- AAMI 0.00
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.